Replimune Spotlights Late-Breaking RP1 Data at SITC 2025
The objective response rate was 33.6%, with a median duration of response of 24.8 months, in anti–PD-1–refractory advanced melanoma...
Adarx’s siRNA for CFB Shows Positive Phase 1 Clinical Data
A single subcutaneous 6 mg/kg dose of ADX-038 achieved near-complete alternative pathway inhibition—up to 99.6%—sustained through Day 180 in...
InflaRx Announces Topline Phase 2a Data for INF904 Trial
InflaRx will report topline results on November 10 from a Phase 2a study of INF904, its oral C5a receptor...
IO Biotech Presents Pre-Clinical Cancer Vaccine Data at SITC
Preclinical posters from IO Biotech’s pipeline reported tumor growth inhibition and, in a lung metastasis model, reduced metastatic burden....
Coherus Presents Biomarker Data for anti-CCR8 Antibody CHS-114
CHS-114, a cytolytic anti-CCR8 antibody, reduced intratumoral CCR8+ Tregs by 74% and total FOXP3+ Tregs by 43%, while increasing...
Vadadustat Shows Favorable Mortality, Hospitalization Data
In a post-hoc win-odds analysis of the Phase 3 INNO2VATE program, vadadustat (Vafseo) outperformed darbepoetin alfa on a hierarchical...
ProKidney Presents Full Phase 2 Rilparencel Trial Results
In a Phase 2 open-label study of patients with advanced CKD and diabetes, bilateral renal injections of rilparencel improved...
Atacicept Delivers Remarkable Phase 3 Data for IgA Nephropathy
At 36 weeks, atacicept delivered a 46% reduction from baseline in 24-hour urine protein-to-creatinine ratio and a 42% reduction...
Chemomab Announces New Nebokitug PSC Data at Liver Meeting
Nebokitug maintained favorable safety and sustained biomarker improvement through 48 weeks in the Phase 2 SPRING open-label extension in...
Annovis Alzheimer’s Program Sees Strong Phase 3 Progress
All 84 U.S. sites are active for Annovis Bio’s pivotal Phase 3 Alzheimer’s program, with the first participants reaching...